2015-2023 Business Plan
In the Business Plan for the period 2015-2023, DNDi maintains its commitment to develop treatments for African sleeping sickness, leishmaniasis, and Chagas disease as well as filarial diseases and paediatric HIV. Having transferred its malaria activities to the Medicines for Malaria Venture (MMV), DNDi is also undertaking new research and development (R&D) projects for hepatitis C and mycetoma, two very different diseases that share one key challenge: the existing system of biomedical innovation has failed to deliver safe, effective, quality products that are affordable to poor populations.
The Business Plan 2015-2023 was elaborated through a 24-month process and in-depth consultation with DNDi’s founding partners, governments, key stakeholders, and experts in global health research. It was approved by the Board of Directors in June 2015. The new plan emphasizes DNDi’s commitment to addressing the needs of neglected patients, while allowing for more flexibility to extend the scope of diseases to address current and future unmet and/or urgent patient needs as they arise. A range of operating and support models has been designed to ensure DNDi’s engagement is tailored and appropriate to the need.
DNDi will continue developing its pipeline of over 30 projects for the most neglected diseases. By its 20th anniversary in 2023, DNDi aims to deliver 16 to 18 new treatments with an estimated total budget of EUR 650 million. Importantly, DNDi will use its own experience to forcefully advocate for a global R&D framework that guarantees both innovation and equitable patient access to health technologies.